Health Canada has approved the first RSV vaccine, Arexvy, for adults aged 60 and over.

The vaccine, manufactured by GSK, has shown promising results in clinical trials, with an 82 per cent efficacy in preventing lower respiratory tract disease caused by RSV in seniors compared to a placebo group.

For seniors with underlying medical conditions, the vaccine was found to be 94 per cent effective in preventing RSV-related illnesses.

The RSV season typically spans from late fall to spring in Canada, the risk of transmission and illness in seniors and infants escalates during this period.